• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Point of Care Diagnostics for Emerging Infectious Disease Threats (Dengue Fever, HIV, HPV, STDs, Chagas, TB, and Other IDs): Market Analysis and Technical Considerations

$150.00 – $300.00

Clear
SKU: KLI6429399 Categories: Diagnostics Market Research, Infectious Disease, Point-of-Care Diagnostics Pages: 150
  • Description
  • Table of Contents
  • Latest reports

Description

The World Health Organization has identified a group of diseases that are the world’s most pressing health problems. This represents an opportunity for test manufacturers, particularly in POC testing. Because of their ability to deliver fast results at the point of care, rapid testing is a focus area of healthcare providers and payors in infectious disease prevention. Kalorama Information has been reporting on the rapid test area for several years and has identified the segments with the fastest growth, and infectious disease has surfaced as one of those segments.

This report, Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations), examines this POC segment with a focus on new threats for which there are markets in the developing world and in developed countries.

A Unique Approach: Market and Technical Analysis
Tests can only be marketed if they can be manufactured and if they can function in the healthcare environment. Thus, this report also discusses the technical choices, possibilities and limitations to today’s POC tests especially when they are used in the developing world. Reagent issues, testing on strips, instrumented and non-instrumented tests are coved in this report. These factors will impact what tests will reach the market and how they will function.

An Opportunity For Test Makers
Infectious disease is a broad category, and in some disease areas, diagnostic companies already own market share. Increasingly hospitals and clinics are seeing new infectious disease threats and tests are being developed to assist them. Within the infectious disease testing market, this report details the opportunities that could be found when diseases of the developing world enter the healthcare system of the developed.

This report provides market projections for point of care diagnostics in the developed and developing world for the following infectious diseases:

  • Chagas Disease, Rapid Test Market Forecast to 2015
  • Chikungunya,
  • Rapid Test Market Forecast to 2015
  • Dengue Fever,
  • Rapid Test Market Forecast to 2015
  • HIV,
  • Rapid Test Market Current Size and Forecast to 2015
  • HPV,
  • Rapid Test Market Current Size and Forecast to 2015
  • Leishmaniasis,
  • Rapid Test Market Forecast to 2015
  • Onchocerciasis (River Blindness),
  • Rapid Test Market Forecast to 2015
  • STDs,
  • Rapid Test Market Current Size and Forecast to 2015
  • Tuberculosis,
  • Rapid Test Market Forecast to 2015

In addition the report also provides:

  • The Overall Point of Care Diagnostics Market Statistics
  • Economics of Financial and International Programs
  • Company Profiles of Leaders in the POC Infectious Disease Market
  • Key Players in the Infectious Disease Rapid Test Market
  • Developed and Developing World Opportunities
  • Test Volumes in Developing Countries
  • Review of Test Products Currently on the Market
  • Climate, Water Use and Sample Prep Considerations
  • EMR and Connectivity Issues
  • Tests in Development
  • The Role of Drug Resistance
  • Disease Statistics
  • POC and Infrastructure Needs
  • Comparison of Test Modalities and Sample Collection Methods

 

Two Industry Experts Provide Unique Insights
Shara Rosen is Kalorama Information’s lead diagnostic industry analyst. She is the author of seven best-selling editions of The Worldwide Market for In Vitro Diagnostics, as well as scores of other titles on segments of the IVD Industry.

Brendan O’Farrell is the President of Diagnostic Consulting Network (www.dcndx.com), a provider of OEM services to developers and manufacturers of rapid assays. Key services include contract rapid assay system development, custom reagent development, industry education and training and consulting services.

Among the topics these experts discuss is the number of competitors who have been successful with efforts in developing countries. The following companies are discussed in this report:

  • 3QBD
  • Abbott Diagnostics Access Bio, Inc.
  • Acon Laboratories, Inc./Innovacon
  • Akers Biosciences, Inc.
  • Akonni Biosystems Inc.
  • Alere
  • American Bionostica, Inc.
  • AT First Diagnostic LLC
  • Beckman Coulter Inc. Becton Dickinson
  • Bhat Bio-tech India (p) Ltd.
  • Biocan Diagnostics Inc.
  • bioLytical Laboratories
  • Biomagnetics Diagnostics Corp.
  • Bio-Manguinhos/FioCruz
  • bioMerieux
  • BioVei Incorporated
  • Burnet Institute
  • California Institute of Technology (Caltech)
  • CapitalBio Corporation
  • Catalysis Foundation for Health
  • Cellestis Ltd
  • Cepheid
  • Chembio Diagnostic Systems, Inc.
  • Clearbridge BioLoc
  • Clinoteck Diagnostics
  • Core Diagnostics
  • CTK Biotech Inc.
  • Diagnostics for All (DFA)
  • Diagnostics for the Real World (DRW)
  • DIALAB
  • DNA Medicine Institute (DMI)
  • Eiken Chemical Co., Ltd.
  • Enigma Diagnostics Limited
  • Epistem Plc
  • FK Biotecnologia
  • Guardian Technologies International
  • Hain Lifescience GmbH
  • Hema Diagnostic Systems (HDS)
  • i MED Laboratories Company Limited
  • InBios International, Inc.
  • Ionian Technologies, Inc.
  • IQuum Inc.
  • Jal Innovation (S) Pte
  • LabNow
  • Lifeassay Diagnostics (Pty) Ltd
  • Linnodee Ltd.
  • LumiQuick Diagnostics, Inc.
  • J. Mitra & Co. Pvt Ltd
  • MP Biomedicals
  • MedMira Inc.
  • Micronics, Inc.
  • Microskia
  • Millennium Biotechnology, Inc. (MBI)
  • Omega Diagnostics Group PLC
  • Partec GmbH
  • PointCare Technologies, Inc.
  • QBC Diagnostics, Inc.
  • QuantuMDx Group
  • Premier Medical Corporation Limited
  • Princeton BioMeditech Corporation
  • Seventh Sense Biosystems, Inc.
  • Signature Mapping Medical Sciences, Inc.
  • Span Diagnostics Ltd.
  • Standard Diagnostics, Inc.
  • Tulip Group
  • VEDA.LAB
  • Veredus Laboratories Pte
  • WAMA Diagnostica
  • Zyomyx Inc.

All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.

For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at http://kaloramakeypoint.blogspot.com/

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Scope and Methodology
  • Emerging Market Trends, diseases and technologies
  • World Demand for Decentralized Testing for Infectious Diseases

CHAPTER TWO: COMMERCIALIZATION OF DECENTRALIZED TEST DEVICES FOR INFECTIOUS DISEASES

  • Overview
  • User Training and Support Services
  • Connectivity Supports Decentralized Testing
  • The Disease Burden
  • Drug Resistance Complicates the Test Landscape
  • An Unmet Need
  • Economics of Financial and International Programs
  • Conclusion

CHAPTER THREE: TECHNICAL CONSIDERATIONS

  • Overview
  • Reagent Issues
  • Instrumented or non-instrumented
  • Diagnostics on Paper Test Strips
  • The Promise of Decentralized Molecular Diagnostics
  • Wireless Communication
  • Miniaturization

CHAPTER FOUR: CHAGAS DISEASE

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER FIVE: CHIKUNGUNYA

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER SIX: DENGUE

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER SEVEN: HIV

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER EIGHT: HPV

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER NINE: LEISHMANIASIS

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER TEN: LEPTOSPIROSIS

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER ELEVEN: MALARIA

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER TWELVE: ONCHOCERCIASIS (RIVER BLINDNESS)

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER THIRTEEN: STDs

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER FOURTEEN: TUBERCULOSIS

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

 

    In Vitro Diagnostic (IVD) Trends and Market Update, 2025
    April 7, 2025
    In Vitro Diagnostics Business Outlook, 2025 (6 Issues)
    April 3, 2025
    Molecular Diagnostics Quarterly Datastream, 2025
    April 2, 2025
    30-Country In Vitro Diagnostic (IVD) Market Atlas, 2025
    March 25, 2025

Related products

  • Placeholder image

    The U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products

    $3,000.00 – $6,000.00
  • Placeholder image

    Molecular Diagnostics for Infectious Disease Testing: Testing volume, cost per test, and market potential

    $995.00 – $1,990.00
  • Placeholder image

    Diagnostics for Emerging Infectious Disease Threats, Volumes I – III

    $3,995.00 – $7,990.00
  • Placeholder image

    Molecular Diagnostics for Inherited Disease Testing: Testing volume, cost per test, and market potential

    $995.00 – $1,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Remote and Wireless Patient Monitoring MarketsCell Culture: The World Market for Media, Sera and Reagents, 3rd Edition
Scroll to top